Citation Impact
Citing Papers
Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
2012
Phthalimide conjugation as a strategy for in vivo target protein degradation
2015 Science
Characterizing and explaining the impact of disease-associated mutations in proteins without known structures or structural homologs
2022 StandoutNobel
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
2013
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
2017
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
2015
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
2016
Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations
2009
CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
2014
miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells
2017
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
2017
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
2016
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
2019 StandoutNobel
The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells
2019
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis
2014
The molecular hallmarks of epigenetic control
2016 Standout
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
2016 StandoutNature
Biomolecular Condensates and Cancer
2021
Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity
2020 StandoutNobel
Breast cancer
2016 Standout
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
2015 Nature
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn
2009
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
2018 StandoutNobel
Targeting cell cycle and hormone receptor pathways in cancer
2013
Tissue-specific tumorigenesis: context matters
2017
Applications of the CRISPR–Cas9 system in cancer biology
2015
Long Noncoding RNAs in Cancer Pathways
2016 Standout
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
2012
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
2014
Enabling functional genomics with genome engineering
2015
The Human Transcription Factors
2018 Standout
Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9
2016
EGF–ERBB signalling: towards the systems level
2006 Standout
Unravelling the genomic targets of small molecules using high-throughput sequencing
2014
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
2014
Non-coding driver mutations in human cancer
2021
A chemical probe toolbox for dissecting the cancer epigenome
2017
The role of enhancers in cancer
2016
A Phase Separation Model for Transcriptional Control
2017
Targeting apoptosis in cancer therapy
2020 Standout
The Genetics of Transcription Factor DNA Binding Variation
2016
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
2018
Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex
2019
Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer
2022
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
2020 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Applications of CRISPR technologies in research and beyond
2016 StandoutNobel
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
2016
Hidradenitis suppurativa
2020 Standout
PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
2013
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
2014
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Structure of the decoy module of human glycoprotein 2 and uromodulin and its interaction with bacterial adhesin FimH
2022 StandoutNobel
The Requirement for Cyclin D Function in Tumor Maintenance
2012
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
2020 Standout
Non-coding Transcription Instructs Chromatin Folding and Compartmentalization to Dictate Enhancer-Promoter Communication and T Cell Fate
2017
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
2021 StandoutNobel
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Cellular senescence: from physiology to pathology
2014 Standout
MDGAs interact selectively with neuroligin-2 but not other neuroligins to regulate inhibitory synapse development
2012 StandoutNobel
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
2016
The Many Substrates of Presenilin/γ-Secretase
2011
Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
2014
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions
2015
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
Breast Cancer Treatment
2019 Standout
Natural and Designed Proteins Inspired by Extremotolerant Organisms Can Form Condensates and Attenuate Apoptosis in Human Cells
2022 StandoutNobel
Comprehensive Description of the N-Glycoproteome of Mouse Pancreatic β-Cells and Human Islets
2011
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
2015
Investigating DNA supercoiling in eukaryotic genomes
2017
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
2016
Cancer Genome Landscapes
2013 StandoutScience
Cas9 interrogates DNA in discrete steps modulated by mismatches and supercoiling
2020 StandoutNobel
Targeting CDK4 and CDK6: From Discovery to Therapy
2015
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
2016 Standout
Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia
2021 StandoutNobel
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
2014
Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment
2015
Mechanisms of Renal Fibrosis
2017 Standout
Kaempferol: A Key Emphasis to Its Anticancer Potential
2019 Standout
2014
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
2015
Liquid phase condensation in cell physiology and disease
2017 StandoutScience
Chemical Glycoproteomics
2016 StandoutNobel
Works of Lars Anders being referenced
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
2014 Science
D-Cyclins Repress Apoptosis in Hematopoietic Cells by Controlling Death Receptor Fas and Its Ligand FasL
2014
A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
2011
Signaling through cyclin D-dependent kinases
2013
Furin-, ADAM 10-, and γ-Secretase-Mediated Cleavage of a Receptor Tyrosine Phosphatase and Regulation of β-Catenin's Transcriptional Activity
2006
Genome-wide determination of drug localization
2013